|
Dear,
Hope all is well with you! I'm Catherine, the technical support from GeneMedi.
Here I want to share with you the PDF document of Products & Solutions collection for COVID-19 diagnostics and vaccine & neutralizing antibody discovery.
We also provide samples for some products, you can reply to apply for samples of your interest.
You could check the details with the PDF document, click to download:
COVID-19 Products validation & publication by GeneMedi's clients
Most of our products are validated and applied by global diagnostic companies, and highly evaluated by them. For example, for some antigen and antibody customers, they said they have obtained good performances of the products, such as their stability and specificity.
Due to the spike protein mutations of various lineages, the absence of detection of the S-gene target, also known as S-gene target failure (SGTF) occurs frequently. Thus, it is better to choose other proteins for diagnosis. Since there are fewer mutations of N protein, it may be more effective to use it to diagnose SARS-CoV-2.
|
Dose-response curve for a half-strip LFA using nucleocapsid protein from two commercially available sources, as measured using a commercially available optical LFA reader. The LOD for the GeneMedi N protein was 0.65 ng/mL (95% CI of 0.53 to 0.77 ng/mL) and for the Genscript N protein was 3.03 ng/mL (95% CI of 0.00 to 7.44 ng/mL).
|
Antibody pairs in the top 5 for both S/N and S-N are ranked in the round 4
|
Besides, here's the summary table for GeneMedi's COVID-19 Vaccine & Antibody Candidates Efficacy Evaluation Solution for new variants of SARS-CoV-2:
|
Information
Collection
|
UK-B.1.1.7
lineage
|
South Africa
501Y.V2
|
P.1 lineage
(B.1.1.28.1, Brazilian variant)
|
Others Variants |
|
|
Spike protein & ACE2 competition binding assay
(Full list of products→)
Human soluble ACE2 protein
|
Spike Protein RBD-N501Y mutant (Details→) |
Spike Protein RBD(K417N, E484K and N501Y mutant) (Details→) |
Spike Protein RBD(K417N, E484K and N501Y mutant) (Details→) |
Spike S6P trimer (F817P, A892P, A899P, A942P, K986P, V987P), V341I, F342L, F342L, V341I, F342L, N354D, D364Y, V367F, R408I, A435S, W436R, K458R, G476S, V483R, N protein (Details→) |
| Spike S-trimer protein D614G mutant (Details→) |
Spike S-trimer protein D614G mutant (Details→) |
| Spike Protein S1 D614G mutant (Details→) |
Spike Protein S1 D614G mutant (Details→) |
| Spike Protein RBD-N501Y mutant (Details→) |
Spike Protein RBD-N501Y mutant (Details→) |
| Spike Protein RBD-E484K mutant (Details→) |
Spike Protein RBD-E484K mutant (Details→) |
|
|
Multi-VariantsTM SARS-CoV2
Pseudovirus Neutralization Assay System
(Full list of products→)
293T-hACE2 stable cell line
|
RBD N501Y mutation (Details→) |
501Y.V2 RBD triple mutation (K417N, E484K and N501Y) Pseudovirus (Details→) |
RBD triple mutation(K417T, E484K and N501Y)+D614G Pseudovirus (Details→) |
S943P, V367F, G476S, V483A, H49Y, Q239, A831V, P1263L, D839Y/N/E-D839Y, D839Y/N/E-D839N, D839Y/N/E-D839E, P2-mutated Spike trimer (Details→) |
| whole mutant B.1.1.7 Pseudovirus (Details→) |
whole mutant 501Y.V2 Pseudovirus (Details→) |
whole mutant Brazilian P.1 Pseudovirus (Details→) |
| B.1.1.7-S1 HV 69-70 Deletion mutation SARS-CoV-2(2019nCoV) Pseudovirus (Details→) |
501Y.V2 E484K mutation Pseudovirus (Details→) |
501Y.V2 E484K mutation Pseudovirus (Details→) |
|
Spike S1 D614G mutation Pseudovirus (Details→) |
Spike S1 D614G mutation Pseudovirus (Details→) |
|
RBD N501Y mutation (Details→) |
RBD N501Y mutation (Details→) |
|
codon-optimized spike mammalian expression vector
(Full list of products→) |
RBD N501Y mutation (Details) |
pCDNA3.1 |
RBD triple mutation (501Y.V2 lineage) |
pCDNA3.1 |
RBD triple mutation (K417T, E484K and N501Y mutant)+D614G |
pCDNA3.1 |
viral vector & mammalian & E.coli Expression system: Spike mutation(D614G, S943P,V367F, G476S, V483A, H49Y, Q239K, A831V, P1263L, D839Y/N/E, D839Y, D839N, D839E), P2-mutated Spike trimer, N protein,S protein (Spike), RBD, D614G, E protein(Envelope), M protein, ORF1ab/3a/6/7/8/10, Nsp1-16, ACE2, TMPRSS2 (Details→) |
| Pre-made adenovirus |
Pre-made adenovirus |
Pre-made adenovirus |
| B.1.1.7 lineage whole mutation |
pCDNA3.1 |
501Y.V2 lineage whole mutation |
pCDNA3.1 |
P.1 lineage whole mutation |
pCDNA3.1 |
| Pre-made adenovirus |
Pre-made adenovirus |
Pre-made adenovirus |
| S1 HV 69-70 Deletion mutation(ΔH69/ΔV70,B.1.1.7 lineage) |
pCDNA3.1 |
E484K mutation(501Y.V2 lineage) |
pCDNA3.1 |
E484K mutation(501Y.V2 lineage) |
pCDNA3.1 |
| Pre-made adenovirus |
Pre-made adenovirus |
Pre-made adenovirus |
|
RBD N501Y mutation(B.1.1.7 RBD) |
pCDNA3.1 |
RBD N501Y mutation(B.1.1.7 RBD) |
pCDNA3.1 |
| Pre-made adenovirus |
Pre-made adenovirus |
| D614G mutation |
pCDNA3.1 |
D614G mutation |
pCDNA3.1 |
D614G mutation |
pCDNA3.1 |
| Pre-made adenovirus |
Pre-made adenovirus |
Pre-made adenovirus |
Please let me know if there is any opportunity to be your supplier and collaborator in COVID-19 related products.
Looking forward to your reply.
Catherine
Technical support from GeneMedi
Whatsapp ID:+86 18317083382
GeneMedi Biotechnology
Address: 6th Floor, Buiding No.2, Kangxin Road 3377, Shanghai, China
Website: www.genemedi.net
unsubscribe
|